Prebiotics Progress Shifts in the Intestinal Microbiome That Benefits Patients with Type 2 Diabetes Mellitus
Hypoglycemic medications that could be co-administered with prebiotics and functional foods can potentially reduce the burden of metabolic diseases such as Type 2 Diabetes Mellitus (T2DM). The efficacy of drugs such as metformin and sulfonylureas can be enhanced by the activity of the intestinal mic...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/13/9/1307 |
| _version_ | 1797581124894982144 |
|---|---|
| author | Luis Vitetta Nick N. Gorgani Gemma Vitetta Jeremy D. Henson |
| author_facet | Luis Vitetta Nick N. Gorgani Gemma Vitetta Jeremy D. Henson |
| author_sort | Luis Vitetta |
| collection | DOAJ |
| description | Hypoglycemic medications that could be co-administered with prebiotics and functional foods can potentially reduce the burden of metabolic diseases such as Type 2 Diabetes Mellitus (T2DM). The efficacy of drugs such as metformin and sulfonylureas can be enhanced by the activity of the intestinal microbiome elaborated metabolites. Functional foods such as prebiotics (e.g., oligofructose) and dietary fibers can treat a dysbiotic gut microbiome by enhancing the diversity of microbial niches in the gut. These beneficial shifts in intestinal microbiome profiles include an increased abundance of bacteria such as <i>Faecalibacterium prauznitzii</i>, <i>Akkermancia muciniphila</i>, <i>Roseburia species</i>, and <i>Bifidobacterium</i> species. An important net effect is an increase in the levels of luminal SCFAs (e.g., butyrate) that provide energy carbon sources for the intestinal microbiome in cross-feeding activities, with concomitant improvement in intestinal dysbiosis with attenuation of inflammatory sequalae and improved intestinal gut barrier integrity, which alleviates the morbidity of T2DM. Oligosaccharides administered adjunctively with pharmacotherapy to ameliorate T2DM represent current plausible treatment modalities. |
| first_indexed | 2024-03-10T22:59:42Z |
| format | Article |
| id | doaj.art-cb7b7800caf54d49b1a458747d09715b |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-10T22:59:42Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-cb7b7800caf54d49b1a458747d09715b2023-11-19T09:45:08ZengMDPI AGBiomolecules2218-273X2023-08-01139130710.3390/biom13091307Prebiotics Progress Shifts in the Intestinal Microbiome That Benefits Patients with Type 2 Diabetes MellitusLuis Vitetta0Nick N. Gorgani1Gemma Vitetta2Jeremy D. Henson3Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, AustraliaOzStar Therapeutics Pty Ltd., Pennant Hills, NSW 2120, AustraliaGold Coast University Hospital, Southport, QLD 4215, AustraliaPrince of Wales Clinical School, University of New South Wales, Sydney, NSW 2052, AustraliaHypoglycemic medications that could be co-administered with prebiotics and functional foods can potentially reduce the burden of metabolic diseases such as Type 2 Diabetes Mellitus (T2DM). The efficacy of drugs such as metformin and sulfonylureas can be enhanced by the activity of the intestinal microbiome elaborated metabolites. Functional foods such as prebiotics (e.g., oligofructose) and dietary fibers can treat a dysbiotic gut microbiome by enhancing the diversity of microbial niches in the gut. These beneficial shifts in intestinal microbiome profiles include an increased abundance of bacteria such as <i>Faecalibacterium prauznitzii</i>, <i>Akkermancia muciniphila</i>, <i>Roseburia species</i>, and <i>Bifidobacterium</i> species. An important net effect is an increase in the levels of luminal SCFAs (e.g., butyrate) that provide energy carbon sources for the intestinal microbiome in cross-feeding activities, with concomitant improvement in intestinal dysbiosis with attenuation of inflammatory sequalae and improved intestinal gut barrier integrity, which alleviates the morbidity of T2DM. Oligosaccharides administered adjunctively with pharmacotherapy to ameliorate T2DM represent current plausible treatment modalities.https://www.mdpi.com/2218-273X/13/9/1307prebioticsintestinal microbiomeshort chain fatty acidsbutyratefunctional foodsType 2 Diabetes Mellitus |
| spellingShingle | Luis Vitetta Nick N. Gorgani Gemma Vitetta Jeremy D. Henson Prebiotics Progress Shifts in the Intestinal Microbiome That Benefits Patients with Type 2 Diabetes Mellitus Biomolecules prebiotics intestinal microbiome short chain fatty acids butyrate functional foods Type 2 Diabetes Mellitus |
| title | Prebiotics Progress Shifts in the Intestinal Microbiome That Benefits Patients with Type 2 Diabetes Mellitus |
| title_full | Prebiotics Progress Shifts in the Intestinal Microbiome That Benefits Patients with Type 2 Diabetes Mellitus |
| title_fullStr | Prebiotics Progress Shifts in the Intestinal Microbiome That Benefits Patients with Type 2 Diabetes Mellitus |
| title_full_unstemmed | Prebiotics Progress Shifts in the Intestinal Microbiome That Benefits Patients with Type 2 Diabetes Mellitus |
| title_short | Prebiotics Progress Shifts in the Intestinal Microbiome That Benefits Patients with Type 2 Diabetes Mellitus |
| title_sort | prebiotics progress shifts in the intestinal microbiome that benefits patients with type 2 diabetes mellitus |
| topic | prebiotics intestinal microbiome short chain fatty acids butyrate functional foods Type 2 Diabetes Mellitus |
| url | https://www.mdpi.com/2218-273X/13/9/1307 |
| work_keys_str_mv | AT luisvitetta prebioticsprogressshiftsintheintestinalmicrobiomethatbenefitspatientswithtype2diabetesmellitus AT nickngorgani prebioticsprogressshiftsintheintestinalmicrobiomethatbenefitspatientswithtype2diabetesmellitus AT gemmavitetta prebioticsprogressshiftsintheintestinalmicrobiomethatbenefitspatientswithtype2diabetesmellitus AT jeremydhenson prebioticsprogressshiftsintheintestinalmicrobiomethatbenefitspatientswithtype2diabetesmellitus |